ATE324888T1 - Krebstherapie - Google Patents

Krebstherapie

Info

Publication number
ATE324888T1
ATE324888T1 AT00942571T AT00942571T ATE324888T1 AT E324888 T1 ATE324888 T1 AT E324888T1 AT 00942571 T AT00942571 T AT 00942571T AT 00942571 T AT00942571 T AT 00942571T AT E324888 T1 ATE324888 T1 AT E324888T1
Authority
AT
Austria
Prior art keywords
agent
cell
immunotherapeautic
cam
advanced
Prior art date
Application number
AT00942571T
Other languages
English (en)
Inventor
Geoffrey Wayne Krissansen
Jagat Rakesh Kanwar
Lai-Ming Ching
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE324888T1 publication Critical patent/ATE324888T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00942571T 1999-06-14 2000-06-14 Krebstherapie ATE324888T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ33625999 1999-06-14

Publications (1)

Publication Number Publication Date
ATE324888T1 true ATE324888T1 (de) 2006-06-15

Family

ID=19927331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942571T ATE324888T1 (de) 1999-06-14 2000-06-14 Krebstherapie

Country Status (8)

Country Link
US (1) US20040086498A9 (de)
EP (1) EP1189611B1 (de)
JP (1) JP4638098B2 (de)
AT (1) ATE324888T1 (de)
AU (1) AU5717400A (de)
DE (1) DE60027719T2 (de)
ES (1) ES2265948T3 (de)
WO (1) WO2000076497A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
US20070021392A1 (en) * 2000-03-31 2007-01-25 Davis Peter D Divided dose therapies with vascular damaging activity
NZ534190A (en) * 2000-03-31 2007-05-31 Angiogene Pharm Ltd Divided dose therapies with vascular damaging activity
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
GB2384428A (en) * 2002-01-29 2003-07-30 Thromb X Nv Inhibitors of HIF
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
PT2264172T (pt) 2002-04-05 2017-12-06 Roche Innovation Ct Copenhagen As Compostos oligoméricos para a modulação da expressão do hif-1α.
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP2305813A3 (de) 2002-11-14 2012-03-28 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2004066949A2 (en) * 2003-01-28 2004-08-12 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
DE602004022921D1 (de) * 2003-01-31 2009-10-15 Rexahn Corp Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
FR2835838B1 (fr) * 2003-02-06 2007-11-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription
CA2463464A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
WO2005032486A2 (en) * 2003-10-02 2005-04-14 Duke University A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
US7618947B2 (en) * 2004-08-25 2009-11-17 Isis Pharmaceuticals, Inc. Modulation of HIF-1 beta expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
DK1833840T3 (da) 2004-11-09 2010-10-18 Santaris Pharma As Micromirs
US20100297112A1 (en) * 2005-08-26 2010-11-25 Antisoma Research Limited Combinations comprising dmxaa for the treatment of cancer
BR112014027834A2 (pt) * 2012-05-23 2017-08-08 Univ Ohio State composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
EP2991655B1 (de) 2013-04-29 2024-04-10 Memorial Sloan Kettering Cancer Center Zusammensetzungen und verfahren zur veränderung der signalisierung sekundärer botenstoffe
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
EP3653637A1 (de) 2013-05-18 2020-05-20 Aduro BioTech, Inc. Zusammensetzungen und verfahren zur aktivierung einer vom stimulator der interferon-genen abhängigen signalisierung
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3071209A4 (de) * 2013-11-19 2017-08-16 The University of Chicago Verwendung von stachelagonisten als krebsbehandlung
US11058758B2 (en) 2014-11-20 2021-07-13 National Institutes Of Biomedical Innovation, Health And Nutrition TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
ATE102616T1 (de) * 1986-12-23 1994-03-15 Warner Lambert Co Verbindungen mit antitumoralen und antibakteriellen eigenschaften.
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
US5075287A (en) * 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
JPH03116857A (ja) * 1989-09-29 1991-05-17 Mitsui Petrochem Ind Ltd 発光または受光装置
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
JPH0940690A (ja) * 1995-05-23 1997-02-10 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US5977077A (en) * 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5817684A (en) * 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
US5914340A (en) * 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
US5998454A (en) * 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
DE19721211A1 (de) * 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
AU3822701A (en) * 2000-02-17 2001-08-27 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
US20030003092A1 (en) 2003-01-02
EP1189611B1 (de) 2006-05-03
DE60027719T2 (de) 2007-04-26
ES2265948T3 (es) 2007-03-01
AU5717400A (en) 2001-01-02
US20040086498A9 (en) 2004-05-06
JP2003501460A (ja) 2003-01-14
WO2000076497A1 (en) 2000-12-21
DE60027719D1 (de) 2006-06-08
JP4638098B2 (ja) 2011-02-23
EP1189611A4 (de) 2003-05-02
EP1189611A1 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
ATE324888T1 (de) Krebstherapie
Mathews Protective effect of β-carotene against lethal photosensitization by haematoporphyrin
Serša et al. Electrochemotherapy: variable anti-tumor effect on different tumor models
MY121548A (en) Compounds and methods for the treatment of cancer
EP1119362A4 (de) Verwendungsmethode von tetracyclinverbindungen zur steigerung der interleukin-10 produktion
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
JPH01254623A (ja) スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬
NO993258L (no) Peptid-lipidkonjugater, liposomer og liposomal legemiddelavlevering
Overgaard Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
Floersheim et al. Protection against ionising radiation and synergism with thiols by zinc aspartate
SE9704549D0 (sv) Drug delivery system
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
Purohit et al. Experimental evaluation of the glucose antimetabolite, 2-deoxy-D-glucose (2-DG) as a possible adjuvant to radiotherapy of tumors: I. Kinetics of growth and survival of ehrlich ascites tumor cells (EATC) in vitro and of growth of solid tumors after 2-DG and X-irradiation
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
NO20021011L (no) Fremgangsmåte og formulering for tumortilbakegang og suppresjon av cancerceller
Zhou et al. An ultrastructural study of human bladder cancer treated by photodynamic therapy
AU1703195A (en) Verotoxin pharmaceutical compositions and medical treatments therewith
Gevorkyan et al. Anticancer efficacy of hydroxyethylthiamine diphosphate in vivo
Lambin et al. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity
CY1107455T1 (el) Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη
KR100674604B1 (ko) 싸이클릭다이펩타이드를 주성분으로 하는 방사선 보호제
Perria PORPHYRINS AS PHOTOTHERAPEUTIC AGENTS FOR TUMORS AND OTHER DISEASES
Horikoshi et al. Effects of TPA, H7 and OAG on the growth and pigmentation of cultured human melanocyte
Nakano et al. Ganglioside analysis of metastatic malignant melanoma with unknown primary lesion: Comparison of the gangliodise compositions between the cutaneous and the ovarian lesions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties